Denied Rituxan? You Still Have Options.
Rituxan (rituximab) is used for a range of conditions including rheumatoid arthritis, certain types of non-Hodgkin lymphoma, chronic lymphocytic leukemia, and several other serious diseases. With biosimilar versions of rituximab now available, many insurance plans have restructured their formularies — and brand Rituxan may now face formulary exclusions or step therapy requirements favoring biosimilars. Prior authorization requirements are stringent regardless of which version your doctor prescribed, and documentation gaps are a common cause of initial denials.
Option 1: Appeal Your Denial
Whether the denial is for brand Rituxan or a rituximab biosimilar, your appeal should focus on your diagnosis, your prior treatment history, and why rituximab — or the specific formulation your doctor chose — is the appropriate next step. For oncology cases especially, urgency should be clearly documented. Ellen can help you draft your appeal letter.
Option 2: Explore Clinical Trials
Rituximab and anti-CD20 therapies continue to be studied across oncology and rheumatology. Trials may study rituximab, next-generation anti-CD20 agents, or entirely new approaches for your condition. For cancer indications, trials can be especially important when standard treatment access is blocked. Search ClinicalTrials.gov for "rituximab" or your specific condition to see what's available near you.
Option 3: Patient Assistance Programs
Genentech offers access support programs for Rituxan through their Access Solutions service. For oncology patients, the Leukemia and Lymphoma Society (lls.org) provides co-pay assistance and patient navigation support. The Arthritis Foundation (arthritis.org) can also connect rheumatoid arthritis patients to financial assistance resources.
For a complete guide to Rituxan financial assistance — including copay cards, free drug programs, and independent foundations — see our financial assistance page for Rituxan.
Ellen can help you figure out your next step. Start with Ellen →
Frequently Asked Questions
Why was Rituxan denied?
With multiple rituximab biosimilars now on the market, formulary exclusions of brand Rituxan are increasingly common — plans may cover biosimilar rituximab but not the brand. Step therapy requirements may also apply, particularly for rheumatoid arthritis, where insurers often require trying other biologics first. Prior authorization gaps, missing diagnosis documentation, or requests for uses that fall outside the plan's approved indications are other common reasons. Your denial letter will specify the cause.
Can I get Rituxan through a clinical trial?
Yes. Rituximab and anti-CD20 therapies are studied in trials across oncology and autoimmune conditions, and eligible participants often receive the study medication at no cost. Trials may study rituximab itself, biosimilars, or next-generation therapies in the same class. For lymphoma or other cancer diagnoses, your oncologist will be your best guide to current trial options. You can also browse at ClinicalTrials.gov.
How long does a Rituxan appeal take?
Standard internal appeals resolve within 30 days. Expedited appeals, when your doctor documents medical urgency, must be decided within 72 hours. If your internal appeal is denied, an independent external review typically takes up to 45 days. For cancer diagnoses, urgency should be clearly documented from the start to qualify for faster review timelines. Talk to your doctor before making any decisions about your treatment.